Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non-Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247-56

European Urology

Volumn 57, Issue 2, 2010, Pages e7-

  Lamm, Donald ^a   Böhle, Andreas ^b   Palou, Joan ^c   Persad, Raj ^d   Brausi, Maurizio ^e   Colombel, Marc ^f   Akaza, Hideyuki ^g   Buckley, Roger ^h  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b HELIOS AGNES KARLL HOSPITAL   (Germany)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^e AUSL Modena   (Italy)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h NORTH YORK GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; INTERFERON; MITOMYCIN C; THIOTEPA; VITAMIN;

BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT CODING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 72449187450     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.10.033     Document Type: Letter

References (15)

1. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
2. Lamm D.L., and Torti F. Bladder cancer, 1996. CA Cancer J Clin 46 (1996) 103-112
3. Ojea A., Nogueira J.L., Solsona E., et al., Members of the CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
4. Hinotsu S., Akaza H., Isaka S., et al. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 67 (2006) 545-549
5. Cheng C.W., Chan S.F., Chan L.W., et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol 12 (2005) 449-455
6. de Reijke T.M., Kurth K.H., Sylvester R.J., et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group phase III trial (30906). J Urol 173 (2005) 405-409
7. Kaasinen E., Wijkström H., Malmström P.-U., et al., The members of the Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 43 (2003) 637-645
8. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., Sylvester R., and members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
9. Malmström P.U., Wijkström H., Lundholm C., Wester K., Busch C., and Norlén B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127
10. Melekos M.D., Zarakovitis I.E., Fokaefs E.D., et al. Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology 53 (1996) 281-288
11. Palou J., Laguna P., Millán-Rodríguez F., Hall R.R., Salvador-Bayarri J., and Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488-1491
12. Friedman D., Mooppan U.M., Rosen Y., and Kim H. The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal urothelium: an experimental study in rats. J Urol 145 (1991) 1060-1063
13. Murphy W.M., Blatnik A.F., Shelton T.B., and Soloway M.S. Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters. J Urol 135 (1986) 840-844
14. Ohtani M., Fukushima S., Okamura T., et al. Effects of intravesical instillation of antitumor chemotherapeutic agents on bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer 54 (1984) 1525-1529
15. Au JL, Badalament RA, Wientjes MG, et al. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Nat Cancer Inst 93:597-604.